1 / 35

EFFECTS OF DEXMEDITOMIDINE INFUSION FOR FESS UNDER LOCAL ANAESTHESIA

EFFECTS OF DEXMEDITOMIDINE INFUSION FOR FESS UNDER LOCAL ANAESTHESIA. COAUTHORS PROF&HEAD : Dr.I.CHANDRA SEKARAN. MD.,DA. PROF. Dr.S.C.GANESH PRABHU. MD.,DA. ASST.PROF. Dr.SHANMUGA SUNDARAM, MD AUTHOR : Dr. K.M.LAKSHMANA RAJAN (PG)

quon-bell
Télécharger la présentation

EFFECTS OF DEXMEDITOMIDINE INFUSION FOR FESS UNDER LOCAL ANAESTHESIA

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. EFFECTS OF DEXMEDITOMIDINE INFUSION FOR FESS UNDER LOCAL ANAESTHESIA COAUTHORS PROF&HEAD : Dr.I.CHANDRA SEKARAN. MD.,DA. PROF. Dr.S.C.GANESH PRABHU. MD.,DA. ASST.PROF. Dr.SHANMUGA SUNDARAM, MD AUTHOR : Dr. K.M.LAKSHMANA RAJAN (PG) INSTITUTE OF ANAESTHESILOGY,MMC,MADURAI

  2. INTRODUCTION • FESS - GA / LA • Under LA – Adequate sedation,analgesia, with nil or minimal side effects • Patient’s comfort • Surgeon’s comfort • Need anesthesiologist or anaesthetic agent

  3. AIM • To assess the hemodynamic effects, sedation, and duration of analgesia of DEXMEDETOMIDINE INFUSION in patients undergoing FUNCTIONAL ENDOSCOPIC SINUS SURGERY under local anaethesia

  4. STUDY DESIGN • Ethical committee approval & consent from patients • Prospective, placebo-controlled, randomised double blind study • INCLUSION CRITERIA: - 40 ASA I, II Patients undergoing FESS under local anaesthesia -Age: 18-60Yrs • EXCLUSION CRITERIA: -multiple sinus disease-prolonged surgery -heart block ,hypotension -hypersensitivity to study drugs

  5. METHODOLOGY • Assigned in 2 groups D & S(20 EACH) • Baseline hemodynamic parameters recorded • premedication(45 mins prior) -Inj.pethidine 50mg -glycopyrrolate 0.2mg IM • Nasal cavity packed with 4%Lignocaine & Adrenaline

  6. GROUP D- 15 mins prior to surgery IV bolus of dexmedetomidine 1μg/Kg infusion for 10 min • surgery will be commenced with Infiltration of nasal mucosa - 2%lignocaine & adrenaline • 0.7μg/kg/hr infusion as maintenance • Maintenance infusion stopped 15 mins before the end of surgery • Group S- NS

  7. INTRAOPERATIVE MONITORING • Done by theatre anesthetist • BP-Systolic & diastolic • PR every 10 min • SpO2 • Sedation score- ramsay sedation scale • Grading of bleeding- bleeding graded by same surgeon Brady cardia(HR < 50/min) ,severe hypotension MAP<60mmhg-study drug will be stopped and treated accordingly

  8. POST OP MONITORING • Duration of analgesia-time to reach VAS score >4 • Inj .Diclofenac 75 mg im given • No of episodes of nausea ,vomiting – noted & treated

  9. SEDATION SCORE 1- Patient anxious and agitated or restless 2- Patient co-operative, oriented, and tranquil 3- Patient responds to commands only 4- Patient exhibits brisk response to light glabellar tap or loud auditory stimulus 5- Patient exhibits a sluggish response to light glabellar tap or loud auditory stimulus 6- Patient exhibits no response

  10. GRADING OF BLEEDING Qualitative grading • 1- Cadaveric condition; minimal suction • 2- Minimal bleeding; infrequent suction • 3- Brisk bleeding; frequent suction. • 4- Bleeding covers field after removal of suction. • 5- Uncontrolled bleeding ; Bleeding out of nose on removal of suction.

  11. ANALYSIS • Demographic datas • Hemodynamic parameters-HR,MAP,SPO2 • Sedation score • Bleeding grade • Nausea and vomiting

  12. STATISTICAL ANALYSIS • CHI-SQUARE TEST • MANN-WHITNEY U TEST

  13. DEMOGRAPHIC DATAS

  14. SEX WEIGHT

  15. PRE OP HR & MAP

  16. PRE OP HR PRE OP MAP

  17. 0-15 MINS

  18. 0-15 MINS HR MAP

  19. 0-15 MINS HR MAP

  20. 15-75 MINS

  21. 15-75 MINS HR MAP

  22. 15-75 MINS HR MAP

  23. SPO2

  24. RAMSAY SEDATION SCORE

  25. SEDATION GROUP D GROUP S

  26. BLEEDING GRADE

  27. DURATION OF ANALGESIA

  28. PONV

  29. MECHANISM FOR SEDATION • Hyper polarization of locus ceruleus neurons –2A-Adrenoreceptor subtype • Activation of K+ channels • Inhibition of Ca++ channels • Inhibition of adenylyl cyclase •  Firing rate of locus caeruleus neurons •  Activity in ascending noradrenergic pathway • ACTIVATES NATURAL SLEEP PATHWAYS

  30. ANALGESIC EFFECT 2 Agonists Peripheral nociceptors Inhibit sympathetic- mediated pain Primary afferent neurons Inhibit release of SP and glutamate Second order neurons Inhibit firing Subcortical + cortex Decrease emotive aspects Descending inhibitory pathways Disinhibit A5/A7 noradrenergic pathways

  31. HEMODYNAMIC EFFECTS • Initially acts on peripheral alpha 2 receptors-increase in BP/HR-15 mins • Postsynaptic activation of α2 adrenoceptors in the central nervous system (CNS) • Inhibits sympathetic activity and • Decrease blood pressure and heart rate

  32. SUMMARY • RDB study in 40 pts ASA I & II for FESS under LA • Dexmedetomidine and saline • Hemodynamics ,sedation,bleeding grade,duration of analgesia,PONV • Reduction in HR ,MAP in group D than group S • Slow rising high ramsay sedation score in group D • Better surgical field with low bleeding grade in group D than S • Prolonged duration of pain relief (3.30 hrs to 4 hrs ) in group D than group S(0.40-1.40 hrs) • No respiratory depression in both the groups • Better patient and surgeon’s comfort in group D

  33. CONCLUSION DEXMEDETOMIDINE Good Sedative , Analgesic & Can Be Used As a Hypotensive Anesthetic To Control Bleeding With Out Respiratory Depression For FESS UNDER LOCAL ANAESTHESIA

  34. REFERENCES • EUROPEAN JOURNAL OF ANESTHESIOLOGY JAN 2008 Goksu, S.; Arik, H.; Demiryurek, S.; Mumbuc, S.; Oner, U.; Demiryurek, A. T • J CLIN ANAESTHESIA 2008 SEP • Effectiveness of dexmedetomidine in reducing bleeding during septoplasty and tympanoplasty operations • Ayouglu H ,Yapakci O,Ugur MB,Uzun L,Altunkaya H,Ozer Y,Uyanik R.

  35. Thank You!

More Related